The Michael J. Fox Foundationís Partnering Program is designed to proactively showcase promising research results in the Foundationís portfolio for funders who want to invest in their continued development. By promoting collaboration between our awardees and industry groups, the Foundation aims to propel forward promising projects in Parkinsonís disease research along the drug development pipeline.
The Partnering Program formalizes the process of developing direct, proactive relationships with industry, including advising companies about potential collaborative opportunities. It encourages select awardees to submit public overviews highlighting their organization, team and projects. These overviews will then be made available for review by industry groups. Awardees spanning the Parkinsonís disease drug development pipeline, from basic to clinical research, and from academia and industry alike, will be showcased through this initiative.
Selected for the MJFF Partnering Program 2H 2014 are:
Brown University Institute for Brain Sciences is using bioluminescence to drive optogenetic reactions as a novel, minimally invasive method for regulating neural dynamics in the brain.
Neurolixis is studying the efficacious dose of its selective 5-HTIA agonist NLX-112 to treat levodopa-induced dyskinesia.
NsGene is developing encapsulated cell bio-delivery of Glial cell line-Derived Neurotrophic Factor (GDNF) to protect dopamine neurons.
Sign-up for Emails
Receive regular updates on funding opportunities and other resources.
View Past Partnering Program Projects
See projects selected for previous cycles of the MJFF Partnering Program.
Want to work with us?